Amgen announced today results from Pegfilgrastim and Anti-VEGF Evaluation Study , a Phase 3 trial which evaluated Neulasta in 845 patients receiving FOLFOX or FOLFIRI and bevacizumab for the first-line treatment of locally-advanced or metastatic colorectal cancer.
http://www.freshnews.com/news/752252/amgen-announces-results-from-phase-3-paves-study-evaluating-neulasta-pegfilgrastim-in-p
http://www.freshnews.com/news/752252/amgen-announces-results-from-phase-3-paves-study-evaluating-neulasta-pegfilgrastim-in-p
No comments:
Post a Comment